Clinical Trials Logo

Clinical Trial Summary

Children, adolescents and young adults with high risk relapsed or treatment refractory neuroblastoma (rNB) represent a group of patients with dismal prognosis for whom a recommended standard salvage therapy is currently not available.

The multimodal metronomic approach combining molecular targeted drugs (rapamycin and dasatinib) with conventional chemotherapy (irinotecan and temozolomide) will be investigated in a randomized fashion as new treatment strategy for patients with rNB. The intention is to assess the therapeutic benefit of molecular targeted drugs for the treatment of rNB.

The combination of irinotecan and temozolomide showed activity in the treatment of several solid organ tumors, brain tumors and neuroblastoma. In one study rNB patients received a median of 5 courses of 5 days irinotecan and temozolomide every 3 to 4 weeks with a cumulative dose of 35% lower than in the RIST design. 33% had disease regression with 8% CR or PR. A phase II study in rNB also using irinotecan and temozolomide with a substantially lower intensity showed a response rate of 15%.

The combination of a mTOR inhibitor with a multi-kinase inhibitor demonstrated in preclinical studies a synergistic effect on cell cycle arrest, apoptosis and sensitization for radio- and chemotherapy. It is assumed that this combination of molecular targeted drugs with a tolerable conventional chemotherapy consisting of irinotecan and temozolomide can substantially improve the outcome of this patient population. A group of 20 rNB patients treated with the RIST therapy approach in a compassionate use setting showed an overall survival of 55% at a median of 80 weeks with a tolerable adverse event profile.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01467986
Study type Interventional
Source University of Regensburg
Contact
Status Completed
Phase Phase 2
Start date August 2013
Completion date September 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT03242603 - Immunotherapy of Neuroblastoma Patients Using a Combination of Anti-GD2 and NK Cells Phase 1/Phase 2
Terminated NCT04560166 - Naxitamab and GM-CSF in Combination With IT in Patients With High-Risk Neuroblastoma Phase 2
Recruiting NCT04903899 - 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma Phase 2
Completed NCT02139397 - Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma Phase 1/Phase 2
Recruiting NCT04239092 - 9-ING-41 in Pediatric Patients With Refractory Malignancies. Phase 1
Not yet recruiting NCT06465199 - Difluoromethylornithine (DFMO) and AMXT-1501 for Neuroblastoma, CNS Tumors, and Sarcomas Phase 1/Phase 2
Recruiting NCT03373097 - Anti-GD2 CAR T Cells in Pediatric Patients Affected by High Risk and/or Relapsed/Refractory Neuroblastoma or Other GD2-positive Solid Tumors Phase 1/Phase 2
Recruiting NCT05754684 - Quadruple Immunotherapy for Neuroblastoma Phase 2
Completed NCT02258815 - CH14.18 1021 Antibody and IL2 After Haplo SCT in Children With Relapsed Neuroblastoma Phase 2